Benlysta is the first and only approved autoinjector biologic for both systemic lupus erythematosus and lupus nephritis ...

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

behavioral, and biological benefits in a specific subgroup of 100 early Alzheimer's patients with inflammation markers, the company said. The drug was safe and well-tolerated, the company said, with ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Shares in clinical-stage biotechnology company INmune Bio ($INMB) collapsed over 60% today as it revealed mixed data from its ...

The most common adverse events (AE) were injection site reactions. Additional analyses will be presented at Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-31, 2025 ...

Most of the solicited adverse reactions (SARs) were mild, according to the company, with injection site pain being the most common localized SAR, while fatigue, headache and myalgia were the most ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

[4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported.

Overactive bladder is a big problem as you age. Up to 30 percent of older adults experience incontinence. The problem is more prevalent in women, but the percentage of men with an overactive ...